Inequitable access to medicines for life-threatening conditions for patients in CEE

25 April 2022

Inequitable access to medicines is a particular challenge in Central and Eastern Europe (CEE); where patients often report having late and inconsistent access to essential medicines that are needed for the management of their diseases, according to Medicines for Europe, the trade group representing the generics and biosimilars industry.

The root cause of these challenges is the policy framework in this region, with underinvestment in healthcare along with inefficiencies in the way available resources are allocated. Off patent medicines account for almost 70% of those dispensed in Europe, but their full potential is not being reached in CEE countries. This restricts patient access to medicines, undermining public health in the region.

Governments in the CEE region can improve patient access to medicines by investing in the off-patent sector and encouraging competition from off-patent, essential medicines. These policies should focus on:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK